The Rho Kinase pipeline drugs market research report outlays comprehensive information on the Rho Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Rho Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology, Respiratory, Oncology, and Central Nervous System which include the indications Ocular Hypertension, Glaucoma, Idiopathic Pulmonary Fibrosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Pancreatic Ductal Adenocarcinoma, Unspecified Cancer, Amyotrophic Lateral Sclerosis, and Unspecified Central Nervous System Disorders. It also reviews key players involved in Rho Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Rho Kinase pipeline targets constitutes close to 45 molecules. Out of which, approximately 37 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 4, 2, 6, 3, 2, 17, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 5, and 3 molecule.
Rho Kinase overview
Rho-associated protein kinase (ROCK), also known as Rho kinase, is a serine/threonine kinase that belongs to the AGC family of protein kinases. It is a key regulator of the cytoskeleton and cellular processes such as contraction, motility, morphology, polarity, cell division, and gene expression. ROCK is ubiquitously expressed in all tissue types and plays a critical role in a wide range of physiological and pathological processes.
For a complete picture of Rho Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
